ClearSight’s proprietary, patent-pending formulation features a powerful antimicrobial biopolymer that effectively targets and eliminates bacterial, fungal, and viral infections associated with pink eye. Unlike antibiotics, this biopolymer acts on the bacterial cell wall, preventing the development of bacterial resistance. Furthermore, ClearSight’s biopolymer can remove biofilm, which is a challenging complication often seen in Dry Eye Disease and infections related to contact lens use.

We have completed the development of our formulation, along with pre-clinical testing for anti-bacterial, anti-fungal, and anti-viral activity. We have also initiated our key pre-clinical biofilm study and expect results shortly. In addition, we have partnerships established with our key API supplier, CDMO, and commercial distribution partners.